Key result
ACE inhibitor therapy reduced all-cause mortality and CAD mortality in high-risk African American men with coronary artery disease.
Why the study?
Does ACE inhibitor therapy reduce all-cause and cardiovascular mortality in high-risk African American men with coronary artery disease?
Cohort (n=810)
No
Does ACE inhibitor therapy reduce all-cause and cardiovascular mortality in high-risk African American men with coronary artery disease?
In high-risk African American men with coronary artery disease, ACE inhibitor therapy is associated with a significant reduction in all-cause and cardiovascular mortality despite a higher baseline burden of comorbidities.
Answers are grounded in this paper and cite their sources.
ACE inhibitor use was associated with lower mortality in this cohort; hypothesis-generating and requires randomized confirmation before practice change.
Angiotensin-converting enzyme (ACE) inhibitors have been extensively used for the treatment of patients with cardiovascular disease, but several concerns have been raised about their efficacy in African American (AA) patients with heart failure, hypertension, and left ventricular hypertrophy. In this study the authors assessed the effect of ACE inhibitors on total and cardiovascular mortality in high-risk AA patients with angiographically proven coronary artery disease (CAD). This was a retrospective analysis of 810 AA men who underwent diagnostic coronary angiography between 1995 and 2003. All patients had demonstrable CAD and had undergone a complete ischemic workup. Follow-up was from 3 to 10 years. ACE inhibitors were administered to 237 patients, while the remaining 537 patients were not taking ACE inhibitors. Patients taking ACE inhibitors had significantly more comorbidities (hypertension, diabetes, left ventricular hypertrophy, heart failure, severe CAD) at baseline, compared with patients not taking ACE inhibitors (P<.05 for all comorbidities). Despite the unfavorable baseline profile, patients taking ACE inhibitors had significantly lower mortality from CAD during follow-up than patients who were not taking ACE inhibitors (P=.006). Stroke mortality rates were similar in both groups. Cox regression analysis showed an 80% higher relative risk in patients not receiving ACE inhibitors. These data indicate a substantial benefit from ACE inhibitor therapy in high-risk AA patients with CAD.
No takes yet. Share an insight, caveat, or question.
Papademetriou et al. (2009) conducted a cohort in Coronary artery disease (n=810). ACE inhibitors vs. No ACE inhibitors was evaluated on All-cause mortality (RR 1.8, 95% CI 1.3-2.6, p=0.01). ACE inhibitor therapy reduced all-cause mortality and CAD mortality in high-risk African American men with coronary artery disease.
Synapse has enriched 10 related papers. Consider them for comparative context: